Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC).
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC).
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). Invest New Drugs. 2021 02; 39(1):182-192.
View in:
PubMed
subject areas
Adult
Adult
Aged
Aged
Antineoplastic Combined Chemotherapy Protocols
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Pancreatic Ductal
Carcinoma, Pancreatic Ductal
Dose-Response Relationship, Drug
Dose-Response Relationship, Drug
Fluorouracil
Fluorouracil
Humans
Humans
Interleukin-10
Interleukin-10
Kaplan-Meier Estimate
Kaplan-Meier Estimate
Leucovorin
Leucovorin
Middle Aged
Middle Aged
Neoplasm Staging
Neoplasm Staging
Organoplatinum Compounds
Organoplatinum Compounds
Pancreatic Neoplasms
Pancreatic Neoplasms
Polyethylene Glycols
Polyethylene Glycols
Response Evaluation Criteria in Solid Tumors
Response Evaluation Criteria in Solid Tumors
authors with profiles
Raid Aljumaily